Esperion to Participate in January Investor Meetings

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th, 2023 in San Francisco, California.

J.P. Morgan 41st Annual Healthcare Conference
Sheldon Koenig, CEO, will be making a corporate presentation and hosting 1×1 institutional investor meetings.

Date/Time: January 11th, 2023, 1:30pm PT
Location: The Westin St. Francis Hotel in San Francisco; Georgian Room
Click here to access the webcast.

LifeSci Partners 12th Annual Corporate Access Event
Sheldon Koenig, CEO, Ben Halladay, CFO, and JoAnne Foody, CMO, will be hosting 1×1 institutional investor meetings.

Date/Time: January 9-10th, 2023
Location: Beacon Grand Hotel in San Francisco
To schedule a meeting on the online system managed by LifeSci Partners, please click here to register for the conference.

Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

Contact:
Esperion Corporate Communications
corporateteam@esperion.com


Primary Logo

Related news for (ESPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.